We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+22.21%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$303M
AUM Growth
-$35.4M
Cap. Flow
-$5.7M
Cap. Flow %
-1.88%
Top 10 Hldgs %
52.11%
Holding
73
New
15
Increased
24
Reduced
14
Closed
16

Top Buys

Rank Stock Value
1
RVNC
Revance Therapeutics, Inc.
RVNC
+$8.57M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$6.77M
3
ONC
BeOne Medicines Ltd
ONC
+$5.18M
4
AKRO
Akero Therapeutics
AKRO
+$3.9M
5
VIR icon
Vir Biotechnology
VIR
+$3.77M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$8.48M
2
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$8.4M
3
PFE icon
Pfizer
PFE
+$8.16M
4
JNJ icon
Johnson & Johnson
JNJ
+$7.75M
5
TGTX icon
TG Therapeutics
TGTX
+$7.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.47%
2 Miscellaneous 8.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALPN
26
DELISTED
Alpine Immune Sciences Inc
ALPN
$3.57M 1.18%
347,432
+147,432
+74% +$1.33M
JBIO
27
Jade Biosciences
JBIO
$1.27B
$3.45M 1.14%
5,748
+34
+0.6% +$21.7K
ZNTL icon
28
Zentalis Pharmaceuticals
ZNTL
$378M
$2.82M 0.93%
+100,000
New +$2.4M
KRTX
29
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$2.71M 0.89%
12,500
-5,000
-29% -$1.07M
TARS icon
30
Tarsus Pharmaceuticals
TARS
$3.98B
$2.71M 0.89%
150,000
+70,000
+88% +$1.11M
FOLD
31
DELISTED
Amicus Therapeutics
FOLD
$2.51M 0.83%
200,000
-275,000
-58% -$3.26M
ATXS
32
DELISTED
Astria Therapeutics
ATXS
$2.5M 0.83%
300,173
-149,827
-33% -$1.73M
QURE icon
33
uniQure
QURE
$3.09B
$2.46M 0.81%
215,000
-160,000
-43% -$3.03M
KRYS icon
34
Krystal Biotech
KRYS
$10.6B
$2.35M 0.78%
+20,000
New +$2.04M
VRNA
35
DELISTED
Verona Pharma
VRNA
$2.33M 0.77%
+110,000
New +$2.35M
PHAT icon
36
Phathom Pharmaceuticals
PHAT
$769M
$2.21M 0.73%
+154,250
New +$1.78M
FUSN
37
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$1.93M 0.64%
412,699
+62,699
+18% +$271K
IMGN
38
DELISTED
Immunogen Inc
IMGN
$1.89M 0.62%
100,000
-24,977
-20% -$295K
PMVP icon
39
PMV Pharmaceuticals
PMVP
$69M
$1.76M 0.58%
+280,981
New +$1.47M
WHWK
40
Whitehawk Therapeutics
WHWK
$262M
$1.71M 0.56%
250,000
+100,000
+67% +$777K
RCUS icon
41
Arcus Biosciences
RCUS
$3.78B
$1.52M 0.5%
75,000
– –
RCKT icon
42
Rocket Pharmaceuticals
RCKT
$424M
$1.49M 0.49%
+75,000
New +$1.52M
BCRX icon
43
BioCryst Pharmaceuticals
BCRX
$2.55B
$1.41M 0.46%
200,000
-75,000
-27% -$602K
MORF
44
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$1.15M 0.38%
+20,000
New +$1.04M
INBX
45
DELISTED
Inhibrx, Inc. Common Stock
INBX
$909K 0.3%
+35,000
New +$817K
BTAI icon
46
CALL
BioXcel Therapeutics
BTAI
$2.31M
$866K 0.29%
+8,125
New +$2.71M
SWTX
47
DELISTED
SpringWorks Therapeutics
SWTX
$723K 0.24%
27,578
– –
BBIO icon
48
BridgeBio Pharma
BBIO
$14.6B
$722K 0.24%
42,000
+17,000
+68% +$256K
RNAM
49
DELISTED
Avidity Biosciences
RNAM
$721K 0.24%
65,000
-60,000
-48% -$753K
IOVA icon
50
Iovance Biotherapeutics
IOVA
$3.98B
$704K 0.23%
100,000
-900,000
-90% -$6.44M
1
2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q2 2023 Portfolio in Review

As of Q2 2023, Ghost Tree Capital held 73 positions worth $303M, down 10% from $338M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Ghost Tree Capital's Q2 2023 filing shows 15 new, 24 increased, 14 reduced and 16 closed positions. Its largest new stake was BeOne Medicines Ltd: 22,500 shares worth $4.01M. The largest sale was Axsome Therapeutics, an estimated $8.48M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 78% a quarter earlier, followed by Miscellaneous.

  • Ghost Tree Capital's largest Q2 2023 buy was BeOne Medicines Ltd: 22,500 shares worth $4.01M.
  • Ghost Tree Capital added most to Revance Therapeutics, Inc. in Q2 2023, an estimated $8.57M increase.
  • Ghost Tree Capital's biggest Q2 2023 reduction was Axsome Therapeutics, cutting an estimated $8.48M.
  • Ghost Tree Capital fully exited CTI BioPharma Corp. (DE) Common Stock in Q2 2023, selling an estimated $8.4M.
  • Ghost Tree Capital's ten largest holdings make up 52% of its $303M portfolio in Q2 2023.
  • Ghost Tree Capital opened 15 new positions and closed 16 in Q2 2023.
  • Ghost Tree Capital's portfolio value fell 10% quarter-over-quarter to $303M.

Based on Ghost Tree Capital's 13F filing for Q2 2023, filed 14 Aug 2023.